Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease

In this study we employed an ELISA assay to measure alpha-synuclein protein in lymphomonocytes from 78 PD patients and 78 controls. We correlated protein levels with demographic and clinical characteristics and with the chymotryptic and tryptic activities of the 20S proteasome. Alpha-synuclein level...

Full description

Saved in:
Bibliographic Details
Published inNeurobiology of aging Vol. 31; no. 5; pp. 884 - 885
Main Authors Brighina, Laura, Prigione, Alessandro, Begni, Barbara, Galbussera, Alessio, Andreoni, Simona, Piolti, Roberto, Ferrarese, Carlo
Format Journal Article
LanguageEnglish
Published London Elsevier Inc 01.05.2010
Elsevier
Subjects
Online AccessGet full text
ISSN0197-4580
1558-1497
1558-1497
DOI10.1016/j.neurobiolaging.2008.06.010

Cover

Loading…
More Information
Summary:In this study we employed an ELISA assay to measure alpha-synuclein protein in lymphomonocytes from 78 PD patients and 78 controls. We correlated protein levels with demographic and clinical characteristics and with the chymotryptic and tryptic activities of the 20S proteasome. Alpha-synuclein levels were not significantly different between patients and controls. In control subjects, alpha-synuclein protein levels increased significantly with age and were significantly higher in men compared to women. Proteasome activity was not significantly different between cases and controls. In control group, the 20S chymotryptic activity tended to decrease significantly with increasing age, though it was not correlated to alpha-synuclein levels. The 20S tryptic activity was not significantly correlated to age, but was inversely correlated to alpha-synuclein levels. Our findings suggest that alpha-synuclein levels in lymphomonocytes are affected by age, gender, and by the 20S proteasome activity in control subjects, but they are not useful as a diagnostic biomarker for PD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0197-4580
1558-1497
1558-1497
DOI:10.1016/j.neurobiolaging.2008.06.010